NCT00412620终止2 期
Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Abbott
- 入组人数
- 156
- 试验地点
- 18
- 主要终点
- The Positive and Negative Syndrome Scale
研究概览
简要总结
The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders, Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or schizoaffective disorder.
详细描述
To explore the safety and efficacy of ABT-925 treatment at three different doses for 6 weeks compared with placebo in subjects with a diagnosis of acute exacerbation of schizophrenia or schizoaffective disorder according to DSM-IV-TR criteria (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject has a current primary diagnosis of schizophrenia or schizoaffective disorder; specifically, an acute exacerbation with prominent "active phase" symptoms, as described in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria (and confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision). Subjects with schizophrenia may belong to any of the following subtypes: paranoid, disorganized, catatonic, or undifferentiated.
- •The subject has a The Positive and Negative Syndrome Scale total score of greater than or equal to
- •The subject has a score of greater than 4 ("moderate") on at least 2 out of the following 5 The Positive and Negative Syndrome Scale positive symptoms: delusions, conceptual disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution.
- •The subject is between 18 and 65 years old inclusive at the time of randomization.
- •The subject has a reliable caregiver (if applicable) or an identified responsible (e.g., family member, social worker, nurse) who will support him/her to ensure compliance with treatment and outpatient visits. In addition, the subject must have an adequate place of residence.
- •The subject agrees to be hospitalized for the duration of the Taper off/Washout Period and at least the first fourteen days of the Double-blind Period.
排除标准
- •The subject has a body mass index greater than
- •The subject has any condition that in the opinion of the investigator is likely to place him/her at an unacceptable safety risk by entering the study or by treatment with ABT-
- •The subject has a diagnosis of one or more of the following conditions: another primary Axis I disorder, including schizophreniform disorder, bipolar disorder or major depressive disorder; comorbid Axis II diagnoses, including borderline personality disorder and mental retardation. (Note: a diagnosis of depression not otherwise specified is acceptable for inclusion into the study).
- •The subject has a diagnosis of substance or alcohol disorder (abuse/dependence according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria), excluding nicotine, within one (1) month prior to the beginning of the Screening Period, or in the opinion of the investigator, a disorder that will interfere with the conduct of the study.
- •The subject has a history of substance-induced psychotic disorder in the previous 6 months.
- •The subject has evidence suggestive of treatment-resistant schizophrenia (i.e., lack of significant clinical improvement despite adequate courses and doses of at least two different antipsychotic medications during the previous 2 years; or adequate use of clozapine indicated for treatment-resistant schizophrenia).
- •The subject has serious violent, homicidal or suicidal ideation in the opinion of the investigator.
- •The subject has a screening QT interval corrected by Bazett formula interval of greater than 430 msec if male and greater than 450 msec if female.
- •The subject's Liver Function Tests (Aspartate aminotransferases, Alanine aminotransferase or total bilirubin levels) are not within normal limits at screening.
- •The subject has a diagnosis, history, or a positive serological result suggestive of liver disease including but not limited to hepatitis and Gilbert's Syndrome.
- •The subject has received any of the following treatments within the time periods described: mood stabilizers or antidepressants during the 30 days prior to Screening; electroconvulsive therapy during the 3 months prior to Screening; clozapine during 60 days prior to Screening.
- •The subject is currently receiving treatment with oral psychotropic medications or has received depot neuroleptics within one inter-injection interval.
研究组 & 干预措施
Sugar Pill
Placebo Comparator
干预措施: Placebo (Drug)
Group 1 Part 1 - ABT-925
Experimental
干预措施: ABT-925 (Drug)
Group 1 Part 2 - ABT-925
Experimental
干预措施: ABT-925 (Drug)
Group 2 - ABT-925
Experimental
干预措施: ABT-925 (Drug)
结局指标
主要结局
The Positive and Negative Syndrome Scale
时间窗: Assessed at screening and weekly from baseline through week 42/premature discontinuation
The PANSS (The Positive and Negative Syndrome Scale) assesses the severity of symptoms of schizophrenia over the preceding seven days. The PANSS items are divided into positive, negative, and general psychopathology factors. The PANSS total score is the score of all 30 PANSS items taken together.
次要结局
- Brief Psychiatric Rating Scale(Assessed at screening and weekly from baseline through week 42/premature discontinuation)
- Clinical Global Impression Severity score(Assessed at screening and weekly from baseline through week 42/premature discontinuation)
- Calgary Depression Scale for Schizophrenia Total score(Assessed at screening and weekly from baseline through week 42/premature discontinuation)
- Negative Symptom Assessment(Assessed at screening and weekly from baseline through week 42/premature discontinuation)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity DisorderNCT00528697AbbVie (prior sponsor, Abbott)278
已完成
2 期
Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity DisorderNCT00640419AbbVie (prior sponsor, Abbott)121
终止
2 期
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT00555204Abbott337
已完成
2 期
Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity DisorderNCT00640185AbbVie (prior sponsor, Abbott)160
已完成
2 期
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's DiseaseAlzheimer's DiseaseNCT01137526AbbVie (prior sponsor, Abbott)267